| user: | comp_bio |
| created: | August 2, 2024 |
| karma: | 19 |
| about: | Location: Boston, Massachusetts, USA Remote: Yes / Hybrid / On-Site Willing to relocate: No Technologies: - Fields: Cancer Biology, Cancer Genetics, Population Genetics, Bioinformatics - Coding Languages: Python, R, Bash, Go, Rust - Computational Methods: Sequencing Analysis, Rare Variant Detection, GWAS, Sequence Alignment, Variant Calling, Mendelian Randomization, Polygenic Risk Scoring - Computational Tools: Scikit-learn, Numpy, Matplotlib, Pandas, SciPy, GATK, samtools, Seurat, Git/Github, Cluster Computing, Linux, Google Cloud Computing, AWS, Code Ocean, Random Forest, Deep Learning, K-Nearest Neighbor, Regression, Clustering, UKB, TOPMed, AllofUs, EHR - Wetlab Technologies: Amplicon Sequencing, Liquid Biopsies, NGS, sc-DNASeq, ddPCR, scRNA-Seq, CRISPR-Cas, System, Genome Editing, Cell Culture, ctDNA Résumé/CV: https://github.com/liggettla/resume Email: orb_05daring@icloud.com LinkedIn: https://www.linkedin.com/in/lutheraliggett/ GitHub: https://github.com/liggettla/ I am a scientist with over 15 years of experience, principally with a focus on cancer genetics and computational biology. In most of my research positions I was responsible for both the wet-lab and the computational aspects of my projects. I have worked extensively on detecting rare somatic mutations of the hematopoietic system and used these mutations to model and understand the steps involved in the process of oncogenesis. In graduate school I built one of the most sensitive mutation detecting platforms in the world. I also have spent time translating my research to the clinic to inform physician decision making during cancer treatment. Additionally, I have worked to understand the role of mutation accumulation in the first human gene therapy clinical trials. In my most recent research I have been pursuing a population genetics approach to understand the evolution of somatic mutation rates in humans. Most recently I worked as a Senior Scientist in Computational Biology at a startup in Cambridge that leveraged mitochondrial mutations for lineage tracing of the hematopoietic tissue as a means of diagnosing early cancers. Personal: I spend most of my spare time running, both in the woods, and when i'm late for meetings. |